The economic value of a quadrivalent versus trivalent influenza vaccine.

TitleThe economic value of a quadrivalent versus trivalent influenza vaccine.
Publication TypeJournal Article
Year of Publication2012
AuthorsLee BY, Bartsch SM, Willig AM
JournalVaccine
Volume30
Issue52
Pagination7443-6
Date Published2012 Dec 14
ISSN1873-2518
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Costs and Cost Analysis, Female, Humans, Infant, Influenza Vaccines, Influenza, Human, Male, Middle Aged, Young Adult
Abstract

The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.

DOI10.1016/j.vaccine.2012.10.025
Alternate JournalVaccine
PubMed ID23084849
PubMed Central IDPMC3696129
Grant List1U54GM088491-0109 / GM / NIGMS NIH HHS / United States
5P01HK000086-02 / HK / PHITPO CDC HHS / United States
5R01LM009132-03 / LM / NLM NIH HHS / United States
R01 LM009132 / LM / NLM NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: